Inventus has been named as one of the fastest growing UK tech companies in The Sunday Times 100 Tech 2026.
Inventus ranked 29 in the hardware section of the prestigious top 100.
It is the only technology company on the list dedicated to creating, delivering and managing purpose-built devices and technology solutions exclusively for clinical trials.
The recognition reflects Inventus’ role over the last five years in delivering patient-friendly technology solutions and devices that help keep clinical trials on track for pharmaceutical sponsors and CROs.
While other companies on the Top 100 list develop drugs, software or diagnostics, the unique focus of Inventus lies in delivering and managing connected devices for patients and sites in clinical trials.
Clinical trials are increasingly global, complex and regulated but many still rely on consumer products that were never designed for research use. This can impact the quality and precision of the data which is acquired. It also creates issues around privacy, reliability, patient recruitment and retention.
Inventus was built to close that gap with an end-to-end ecosystem that combines purpose-built patient and site devices, protocol-ready configuration, secure connectivity and centralised Mobile Device Management (MDM) designed exclusively for clinical trials.
Steve Sanghera, Chief Executive and Co-Founder of Inventus said: “Inventus exists to make clinical trials work better for the people at the centre of them, the patients. We are proud of the work we do and this recognition is a validation of our patient-first approach and the standards we’ve built into how our technology is deployed and managed globally.
“In clinical research the smallest failure can create the biggest consequences. We’ve focused on dependable and compliant technology that supports sites, sponsors and patients so that trials run smoothly, consistently and securely wherever they’re happening. Thank you to The Sunday Times for this recognition. And thank you to our amazing team and sponsors who have supported us on our journey so far.”
Since being founded five years ago, Inventus has deployed more than 750,000 purpose-built devices worldwide across 130+ countries with support for 586 languages. It has supported more than 100 clinical trials across a multitude of therapeutic areas in over 80 countries.
Regional warehousing in the UK, Europe and China support rapid deployment, replacement and recovery helping reduce operational risk and maintain continuity across multi-country trials.
You can view the tables online via The Sunday Times here.